Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

December 10, 2019December 16, 2019

Advanced Multiple Myeloma Patients Responding to Janssen’s CAR T-cell Therapy, Trial Data Show

News

Janssen’s investigational CAR T-cell therapy for multiple myeloma, called JNJ-4528 (JNJ-68284528), safely led to early and deep responses in all patients with relapsed or refractory multiple myeloma treated in ... Read more

December 2, 2019December 2, 2019

Ygalo Continues to Show Positive Results in RRMM Patients, Oncopeptides Announces

News

Combination treatment with Ygalo (melflufen) continues to be safe and effective in difficult-to-treat patients with relapsed or refractory multiple myeloma (RRMM), according to the latest results from clinical trials. ... Read more

November 18, 2019November 18, 2019

Ninlaro Prolongs Progression-free Survival in Multiple Myeloma Patients Not Given ASCT, Phase 3 Trial Shows

News

First-line maintenance therapy with Ninlaro (ixazomib) prolongs the time without disease progression in adults with multiple myeloma not treated with an autologous stem cell transplant, meeting its primary goal, data ... Read more

October 18, 2019

Xpovio Leads to Promising Responses in Heavily Treated Multiple Myeloma Patients, Phase 2 Trial Shows

News

Taking Xpovio (selinexor) in combination with the steroid dexamethasone leads to promising responses in heavily treated patients with relapsed or refractory multiple myeloma, a Phase 2 trial shows. The ... Read more

October 14, 2019October 14, 2019

New MMRF Patient Registry Aims to Help Develop Personalized Treatments for Multiple Myeloma

News

Ultimately aiming to advance precision medicine, the Multiple Myeloma Research Foundation (MMRF) has officially launched its Direct-to-Patient (DTP) Registry, allowing people with multiple myeloma to securely submit their health ... Read more

October 7, 2019

Aplidin Prolongs Survival and Time to Disease Progression in Heavily Treated Multiple Myeloma Patients, Phase 3 Trial Shows

News

Aplidin (plitidepsin) in combination with dexamethasone significantly prolonged the survival and time to disease progression or death in heavily treated patients with relapsed or refractory multiple myeloma compared to ... Read more

September 30, 2019October 24, 2019

FDA Approves Darzalex Combo for Newly Diagnosed Multiple Myeloma Patients Eligible for Transplant

News

The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab), in combination with Velcade (bortezomib), thalidomide and dexamethasone (collectively known as VTd), to treat newly diagnosed multiple myeloma patients ... Read more

September 23, 2019

Darzalex Combo Increases Response Rates in Newly Diagnosed Multiple Myeloma Patients, Trial Shows

News

Adding Darzalex (daratumumab) to a combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone — called the VRd combo — increases the proportion of people with multiple myeloma who experience ... Read more

September 18, 2019

Ygalo Continues to Show Promising Activity in Relapsed, Refractory Multiple Myeloma

News

Ygalo (melflufen) combination therapy continues to demonstrate promising results, without significant side effects, in patients with relapsed or refractory multiple myeloma, updated data from two clinical trials show. The ... Read more

September 9, 2019September 13, 2019

Keytruda Plus Standard Therapy Fails to Improve Outcomes in Multiple Myeloma

News

The addition of Keytruda (pembrolizumab) to standard therapy — Revlimid (lenalidomide) or Pomalyst (pomalidomide) in combination with dexamethasone — failed to improve the clinical outcomes of patients with untreated ... Read more

Pin It on Pinterest